GB1341375A - Aminoalkylimidazoles and process for their production - Google Patents

Aminoalkylimidazoles and process for their production

Info

Publication number
GB1341375A
GB1341375A GB1341375DA GB1341375A GB 1341375 A GB1341375 A GB 1341375A GB 1341375D A GB1341375D A GB 1341375DA GB 1341375 A GB1341375 A GB 1341375A
Authority
GB
United Kingdom
Prior art keywords
alkyl
compound
methyl
hydrogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of GB1341375A publication Critical patent/GB1341375A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1341375 Aminoalkylimidazoles SMITH KLINE & FRENCH LABORATORIES Ltd 19 April 1971 [19 Nov 1969] 56512/69 Heading C2C Aminoalkylimidazoles of the Formula I wherein A is a saturated C 1-6 alkyl group, optionally substituted by one or more alkyl or aralkyl groups; R is a substituted or unsubstituted alkyl, aryl or aralkyl group; R 1 is hydrogen, alkyl, phenyl, phenylalkyl or imidazolylalkyl group; R 20 is hydrogen, alkyl optionally substituted by halogen, hydroxy, cyano, carboxy, amino or amidino, or -COY, wherein Y is R 11 O or R 11 NH and R 11 is substituted or unsnbstituted alkyl, aryl or aralkyl or amidine; and X is 0 to 3 provided that when X is 0 and R 20 is hydrogen or a C 1-3 alkyl, R 1 may not be hydrogen, benzyl or C 1-3 alkyl and that when R 1 and R 20 are both hydrogen, A is (CH 2 ) 2 optionally substituted by methyl and X is 1, R may not be methyl or except when substituted in the 4(5) position of the ring, phenyl or benzyl may be prepared by (1) reacting a compound III with R 3 X followed by hydrolysis to produce a compound V wherein R 2 and R 3 are H or substituted or unsubstituted alkyl, aryl or aralkyl; R 4 to R 7 are H, alkyl or aralkyl, R 9 is alkyl, amino alkyl or carboxyalkyl or substituted or unsubstituted aryl or aralkyl and R 8 is R 9 or which produces R 9 on hydrolysis, provided that when R 1 to R 3 are all H and one of R 4 -R 7 is H or methyl when the others of R 4 -R 7 are hydrogen, R 9 may not be methyl, phenyl or benzyl; (ii) reacting a compound IV wherein R 1 to R 8 are as above and additionally R 8 may be hydrogen and Z- is a suitable anion with a nucleophilic reagent, YH, wherein Y is R 11 NH or R 11 O, where R 11 is substituted or unsubstituted alkyl, aryl or aralkyl or an amidine group to produce a compound VII (iii) converting a compound V wherein R 9 and R 1 are hydrogen to the phthalimido compound by treatment with N-carbethoxyphthalimide, which is reacted with R 10 X, where X is halogen and R 10 is optionally substituted aralkyl provided that when R 2 and R 3 are both H and one of R 4 -R 7 is H or methyl when the others of R 4 -R 7 are hydrogen, R 10 may not be benzyl and phthalimido group is removed by hydrolysis to produce V wherein R 1 is H and R 9 is R 10 ; (iv) reacting a compound III in which R 1 is H with a base and then with R 8 X followed by hydrolysis to produce V in which R 9 is H and R 1 is R 9 ; (v) reducing a compound III in which R 1 is R 8 to a compound XV wherein R 12 is R 8 or a reduction product thereof; (v) acylation of a compound XI followed by reduction of the amide to R 13 CH 2 NH- attached to A in XI in place of NH 2 , wherein R 13 is hydrogen, alkyl, phenyl, phenylalkyl or imidazolylalkyl provided that, when R 2 and R 3 are both hydrogen, R 13 may not be H, methyl, ethyl or phenyl; (vi) treating XI, wherein R 2 and R 3 are as defined above provided that when R 3 is H, R 2 may not be H or methyl and when A is a chain of 2 carbon atoms R 2 may not be hydrogen, with formic acid and formaldehyde to give (CH 3 ) 2 N- attached to A in place of NH 2 ; (vii) reacting XI with a carbonyl compound R 19 .CO.R 21 and reducing the Schiff's base so formed to give -NHCH R 19 R 21 attached to A in XI in place of NH 2 , wherein R 19 and R 21 are H, alkyl, phenyl, phenylalkyl or imidazolylalkyl, provided that R 19 and R 21 may not both be phenyl, phenylalkyl or imidazolylalkyl and that, when R 2 and R 3 are both H, CHR 19 R 21 may not be benzyl or a C 1-3 alkyl and when R 19 and R 21 are both H or alkyl, A is a saturated straight chain of 2 carbon atoms optionally substituted by methyl and one of R 2 and R 3 is H, R 2 may not be methyl, phenyl or benzyl; (viii) reacting a compound LVIII wherein X is a halogen with an amine R 14 R 15 NH to produce LVIII in which X is replaced by -NR 14 R 15 , wherein R 14 is alkyl optionally substituted by halogen, hydroxy, cyano, carboxy, amino or amidino; and R 15 is hydrogen, alkyl, phenyl, phenylalkyl, imidazolylalkyl provided that when R 2 and R 3 are both H, R 15 may not be H, C 1-3 alkyl or benzyl and, when R 14 and R 15 are both alkyl, A is a saturated straight chain of 2 carbon atoms optionally substituted by methyl and one of R 2 and R 3 is H, R 2 may not be methyl and R 3 may not be methyl, phenyl or benzyl; (ix) chlorination or bromination of a compound LIX in which R 2 , R 3 , R 15 and A are as defined in process (viii) and X is hydroxy to give a compound LIX in which X is Br or Cl; (x) reacting a compound LX wherein P is phthalimido, with pivaloyloxymethyl halide to introduce the pivaloyloxymethyl radical into the 1-position of the ring followed by reaction with R 16 X, wherein R 16 is optionally substituted alkyl or aralkyl provided that when R 2 and R 3 are both H and A is a saturated straight chain of two carbon atoms optionally substituted by methyl, R 16 may not be methyl, phenyl, or benzyl and removing the protective phthalimido and pivaloyloxymethyl groups to give compound XXVIII (xi) oxidizing R 2 C#C-A-N : P to R 2 CO.CO. A-N : P and cyclizing this product with formaldehyde and ammonium acetate to produce a compound LX in which R 3 is hydrogen followed by hydrolysis to remove the P-group; (xii) reacting a nitrile LIV with a carbonyl R 22 COAr 2 wherein R 22 is H or alkyl and Ar 2 is optionally substituted aryl reducing the C=C in the product followed by reduction of the nitrile to produce LXX in which R 4 is an optionally substituted aryl methyl, provided that R 2 and R 3 may not both be hydrogen; (xiii) reducing the ester group of XXXII to CH 2 OH, followed by halogenation and conversion to the cyanomethyl and reduction thereof to produce LXI (xiv) reacting a compound LXI with N,N<SP>1</SP>- carbonyl di-imidazole to produce a compound VII in which Y is substituted 4-(aminoethyl) imidazole identical to that attached to COY in VII; (xv) ring opening of an imidazole-pyridine by hydrogenation to produce a 4(5)-substituted- 5(4)-aminoethylimidazole; (xvi) addition of acrylonitrile to an N-unsubstituted compound I to produce an N-propionitrile substituted compound I; (xvii) reacting an N-unsubstituted 4(5)-aminoalkylimidazole with a 4(5)-cyanoalkylimidazole to produce a compound I wherein R 1 is imidazolylalkyl. The intermediates III may be formed by reacting a histamine derivative with N,N<SP>1</SP>- carbonyldi-imidazole, and optionally forming the quaternary compound IV by the usual methods. The intermediates XXXII may be produced by cyclizing R 2 COCHXCOOEt, wherein X is halogen or amino and R 2 is alkyl other than methyl, substituted alkyl or substituted or unsubstituted aryl or aralkyl other than phenyl or benzyl with formamide. 2 - Amino - 4 - methyl - 3 - oxo - pentanoate hydrochloride may be prepared by reacting ethyl isobutyryl acetate with nitrous acid to yield ethyl 2 - oximo - 4 - methyl - 3 - oxopentanoate which on hydrogenation yields the required compound. The intermediates R 2 C#C-CH 2 CH 2 N : P may be prepared converting the alcohol R 2 C#CCH 2 CH 2 OH to the tosyl ester and reacting the product with potassium phthalimide. 7-Phenyl hept-3-yn-l-ol may be prepared by reaction of 5-phenyl pent-1-yne with ethylene oxide in the presence of strong base. 2 - Bromo - 4 - phthalimidobutyrophenone may be prepared by reacting 4-chlorobutyrophenone with phthalimide to form 4-phthalimidobutyrophenone which yields the required compound on treatment with bromine. Pharmaceutical compositions of I show antihistamine activity when administered externally or internally with a carrier.
GB1341375D 1969-11-19 1969-11-19 Aminoalkylimidazoles and process for their production Expired GB1341375A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5651269 1969-11-19

Publications (1)

Publication Number Publication Date
GB1341375A true GB1341375A (en) 1973-12-19

Family

ID=10476809

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1341375D Expired GB1341375A (en) 1969-11-19 1969-11-19 Aminoalkylimidazoles and process for their production

Country Status (1)

Country Link
GB (1) GB1341375A (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165378A (en) 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles
US4165377A (en) 1977-04-20 1979-08-21 Ici Americas Inc. Guanidino imidazoles and thiazoles
US4328349A (en) * 1980-10-08 1982-05-04 Sk&F Lab Co. Process for preparing 5-methyl-4-imidazolecarboxylic acid esters
US4374252A (en) * 1980-10-08 1983-02-15 Sk&F Lab Co. Benzyl 5-methyl-4-imidazolecarboxylate
US4375435A (en) * 1981-06-03 1983-03-01 Smith Kline & French Laboratories Limited 3-,4-Dihydroimidazo (3,4-c)-1,3-pyrimidines and 4,5-dihydroimidazo (3,4-c)-1,3-diazepines
EP0081324A2 (en) * 1981-12-04 1983-06-15 Farmos Group Ltd. Substituted pharmacologically acitve imidazole derivatives and their preparation and use
US4443375A (en) * 1981-06-03 1984-04-17 Smith Kline & French Laboratories Limited Tetrahydroimidazo(3,4-c)-1,3-diazocine intermediates for production of guanidines
EP0129254A2 (en) * 1983-06-20 1984-12-27 Diamalt Aktiengesellschaft Process for the preparation of N-tau-substituted histidine derivatives, the N-tau-substituted histidine derivatives and their use
WO1986004331A1 (en) * 1985-01-24 1986-07-31 Pharmacia Ab Carrier-bound histamine, its manufacture and its use
US4818683A (en) * 1984-04-10 1989-04-04 Immunotech Immunoassay for monoamines
US5112738A (en) * 1985-07-03 1992-05-12 Miles Inc. Histamine derivatives, immunogen conjugates and antibodies raised thereto
WO1992012134A2 (en) * 1990-12-28 1992-07-23 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
FR2686084A1 (en) * 1992-01-10 1993-07-16 Bioprojet Soc Civ NEW IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
US5234917A (en) * 1989-12-29 1993-08-10 Finkelstein Joseph A Substituted 5-(alkyl)carboxamide imidazoles
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
WO1995004723A1 (en) * 1993-08-04 1995-02-16 Yamanouchi Pharmaceutical Co., Ltd. Imidazolylalkylamine derivative and pharmaceutical composition thereof
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5547972A (en) * 1991-12-23 1996-08-20 The Boots Company Plc Therapeutic agents useful for treating inflammatory diseases
WO1997047623A1 (en) * 1996-06-10 1997-12-18 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5780642A (en) * 1993-06-22 1998-07-14 Knoll Aktiengesellschaft Imidazole derivatives as therapeutic agents
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
US6915013B2 (en) 1997-06-09 2005-07-05 Hitachi, Ltd. Encoding method using plus and/or minus rounding of images
WO2007000246A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7273956B2 (en) 2002-11-12 2007-09-25 Degussa Ag Process for preparing solutions of alkali metal salts of functionalized alcohols
EP3873890A4 (en) * 2018-11-01 2022-09-07 Ahammune Biosciences Private Limited Novel imidazole compounds, process for the synthesis and uses thereof

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165378A (en) 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles
US4165377A (en) 1977-04-20 1979-08-21 Ici Americas Inc. Guanidino imidazoles and thiazoles
US4234735A (en) 1977-04-20 1980-11-18 Imperial Chemical Industries Limited Guanidino imidazoles and thiazoles
US4262126A (en) 1977-04-20 1981-04-14 Imperial Chemical Industries Limited Guanidine derivatives of imidazoles and thiazoles
US4328349A (en) * 1980-10-08 1982-05-04 Sk&F Lab Co. Process for preparing 5-methyl-4-imidazolecarboxylic acid esters
US4374252A (en) * 1980-10-08 1983-02-15 Sk&F Lab Co. Benzyl 5-methyl-4-imidazolecarboxylate
US4375435A (en) * 1981-06-03 1983-03-01 Smith Kline & French Laboratories Limited 3-,4-Dihydroimidazo (3,4-c)-1,3-pyrimidines and 4,5-dihydroimidazo (3,4-c)-1,3-diazepines
US4443375A (en) * 1981-06-03 1984-04-17 Smith Kline & French Laboratories Limited Tetrahydroimidazo(3,4-c)-1,3-diazocine intermediates for production of guanidines
EP0081324A2 (en) * 1981-12-04 1983-06-15 Farmos Group Ltd. Substituted pharmacologically acitve imidazole derivatives and their preparation and use
EP0081324A3 (en) * 1981-12-04 1983-12-07 Farmos Group Ltd. Substituted pharmacologically acitve imidazole derivatives and their preparation and use
EP0129254A2 (en) * 1983-06-20 1984-12-27 Diamalt Aktiengesellschaft Process for the preparation of N-tau-substituted histidine derivatives, the N-tau-substituted histidine derivatives and their use
EP0129254A3 (en) * 1983-06-20 1987-04-08 Diamalt Aktiengesellschaft Process for the preparation of n-tau-substituted histidine derivatives, the n-tau-substituted histidine derivatives and their use
US4818683A (en) * 1984-04-10 1989-04-04 Immunotech Immunoassay for monoamines
WO1986004331A1 (en) * 1985-01-24 1986-07-31 Pharmacia Ab Carrier-bound histamine, its manufacture and its use
US5112738A (en) * 1985-07-03 1992-05-12 Miles Inc. Histamine derivatives, immunogen conjugates and antibodies raised thereto
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
US5234917A (en) * 1989-12-29 1993-08-10 Finkelstein Joseph A Substituted 5-(alkyl)carboxamide imidazoles
WO1992012134A2 (en) * 1990-12-28 1992-07-23 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
WO1992012134A3 (en) * 1990-12-28 1992-08-20 Neurogen Corp Certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5428164A (en) * 1990-12-28 1995-06-27 Neurogen Corporation Certain 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5547972A (en) * 1991-12-23 1996-08-20 The Boots Company Plc Therapeutic agents useful for treating inflammatory diseases
WO1993014070A2 (en) * 1992-01-10 1993-07-22 Institut National De La Sante Et De La Recherche Medicale Novel imidazole derivatives, their preparation and therapeutic applications
US5708171A (en) * 1992-01-10 1998-01-13 Institut National De La Sante Et De La Recherche Medicale Imidazole derivatives for pharmaceutical use
WO1993014070A3 (en) * 1992-01-10 1993-08-19 Inst Nat Sante Rech Med Novel imidazole derivatives, their preparation and therapeutic applications
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
FR2686084A1 (en) * 1992-01-10 1993-07-16 Bioprojet Soc Civ NEW IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
US5559113A (en) * 1992-01-10 1996-09-24 Institut National De La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
US5780642A (en) * 1993-06-22 1998-07-14 Knoll Aktiengesellschaft Imidazole derivatives as therapeutic agents
WO1995004723A1 (en) * 1993-08-04 1995-02-16 Yamanouchi Pharmaceutical Co., Ltd. Imidazolylalkylamine derivative and pharmaceutical composition thereof
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997047623A1 (en) * 1996-06-10 1997-12-18 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US6915013B2 (en) 1997-06-09 2005-07-05 Hitachi, Ltd. Encoding method using plus and/or minus rounding of images
US7273956B2 (en) 2002-11-12 2007-09-25 Degussa Ag Process for preparing solutions of alkali metal salts of functionalized alcohols
WO2007000246A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US8518976B2 (en) 2005-06-28 2013-08-27 Sanofi Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP3873890A4 (en) * 2018-11-01 2022-09-07 Ahammune Biosciences Private Limited Novel imidazole compounds, process for the synthesis and uses thereof

Similar Documents

Publication Publication Date Title
GB1341375A (en) Aminoalkylimidazoles and process for their production
US6638935B2 (en) Heteroary1 derivatives and their use as medicaments
GB1173783A (en) New Biologically Active Derivatives of Piperazine and Process for manufacture thereof
GB1351430A (en) Substituted 1,2,4-triazole derivatives
GB1324469A (en) Derivatives of benzodiazepines
US4015011A (en) Phenylalkylamines and salts thereof
Effenberger et al. A convenient synthesis of (S)-2-azidonitriles,(S)-2-aminonitriles and (S)-1, 2-diamines
GB1367598A (en) Derivatives of delta 1-pyrroline their method of preparation and their applications
ES346521A1 (en) N-(sulfonylcarbamoyl)-bornano-(3&#39;,2&#39;:4,5)-oxazolidin-3-ones
GB1493048A (en) Imadazo-(2,1-b)thiazoles
GB1095184A (en) Phenylalanine derivatives
Davey Synthesis of 6-phenylimidazo [1, 2-a] pyrazin-8-one and 1-methyl-6-phenylimidazo [1, 5-a] pyrazin-8-one via quaternary intermediates
US4146645A (en) Hypertensive phenylalkylamines and salts thereof
Romea et al. Nitrosation of hindered amides
US3823134A (en) Dichloro-alpha,alpha,alpha-trifluorotoluamides
US4438121A (en) Isoquinoline amidoxime derivatives
Wiley et al. Three Chemically Related Metabolites of Streptomyces. II. Structural Studies1
CN114437050B (en) Deprotection agent for halofuginone intermediate and application thereof
US3694449A (en) 2-SUBSTITUTED -3a,4,5,6,7,7a-HEXAHYDRO-5a,6,7,8,9,9a-HEXAHYDRO-9 A-HYDROXYPYRIDO (2,1-b) BENZOTHIAZOLIUM HALIDES
CA1045135A (en) Pyrrolo(3,4-d)pyrimidines and methods for their preparation
GB1238693A (en)
Kristol et al. Reactions of 1, 1, 2, 2-tetrachloro-3, 4-bis (dichloromethylene) cyclobutane with amines
US6858744B2 (en) Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
Major et al. Vincaminyl Alcohol and Vincamine Nitrite
GB1175676A (en) Indeno-Pyridine Derivatives

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee